Optimization of scarless human stem cell genome editing

L Yang, M Guell, S Byrne, JL Yang… - Nucleic acids …, 2013 - academic.oup.com
L Yang, M Guell, S Byrne, JL Yang, A De Los Angeles, P Mali, J Aach, C Kim-Kiselak…
Nucleic acids research, 2013academic.oup.com
Efficient strategies for precise genome editing in human-induced pluripotent cells (hiPSCs)
will enable sophisticated genome engineering for research and clinical purposes. The
development of programmable sequence-specific nucleases such as Transcription Activator-
Like Effectors Nucleases (TALENs) and Cas9-gRNA allows genetic modifications to be
made more efficiently at targeted sites of interest. However, many opportunities remain to
optimize these tools and to enlarge their spheres of application. We present several …
Abstract
Efficient strategies for precise genome editing in human-induced pluripotent cells (hiPSCs) will enable sophisticated genome engineering for research and clinical purposes. The development of programmable sequence-specific nucleases such as Transcription Activator-Like Effectors Nucleases (TALENs) and Cas9-gRNA allows genetic modifications to be made more efficiently at targeted sites of interest. However, many opportunities remain to optimize these tools and to enlarge their spheres of application. We present several improvements: First, we developed functional re-coded TALEs (reTALEs), which not only enable simple one-pot TALE synthesis but also allow TALE-based applications to be performed using lentiviral vectors. We then compared genome-editing efficiencies in hiPSCs mediated by 15 pairs of reTALENs and Cas9-gRNA targeting CCR5 and optimized ssODN design in conjunction with both methods for introducing specific mutations. We found Cas9-gRNA achieved 7–8× higher non-homologous end joining efficiencies (3%) than reTALENs (0.4%) and moderately superior homology-directed repair efficiencies (1.0 versus 0.6%) when combined with ssODN donors in hiPSCs. Using the optimal design, we demonstrated a streamlined process to generated seamlessly genome corrected hiPSCs within 3 weeks.
Oxford University Press